Healthcare / Medical Instruments & SuppliesTokyo
$1728.00
+7.00 (+0.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $68.5B · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$281.8B
P/E
23.5x
↑EV/EBITDA
9.2x
↓ROE
2.0%
↑Gross Margin
29.6%
↓Debt/Equity
2.52
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.2%
FCF CAGR
+0.1%
FCF margin
10.6%
FCF / Net income
13.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $644.59B · net income $5.11B · FCF $68.46B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $644.59B | $644.59B | $586.78B | $545.20B | $494.79B |
| Net Income | $5.11B | $5.11B | $11.11B | $4.57B | $13.46B |
| EBITDA | $92.58B | $92.58B | $84.62B | $70.02B | $73.54B |
| EPS | 27.78 | 27.78 | 60.35 | 24.85 | 77.42 |
| Gross Margin | 29.6% | 29.6% | 29.2% | 30.0% | 30.2% |
| Operating Margin | 4.1% | 4.1% | 3.8% | 3.3% | 4.8% |
| Net Margin | 0.8% | 0.8% | 1.9% | 0.8% | 2.7% |
| Balance Sheet | |||||
| Debt/Equity | 2.52 | 2.52 | 2.73 | 2.94 | 3.05 |
| Current Ratio | 1.39 | 1.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $68.46B | $68.46B | $72.94B | $10.39B | $68.21B |
| Returns | |||||
| ROE | 2.0% | 2.0% | 4.8% | 2.2% | 7.3% |
| Valuation | |||||
| P/E | 23.48 | 23.48 | 20.91 | 40.44 | 13.08 |
| EV/EBITDA | 9.16 | 9.16 | 9.08 | 10.01 | 8.78 |
| P/B | 1.26 | 1.26 | 1.00 | 0.90 | 0.95 |
| Growth & Yield | |||||
| Revenue Growth | 9.9% | 9.9% | 7.6% | 10.2% | — |
| EPS Growth | -54.0% | -54.0% | 142.9% | -67.9% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
76.7%
EPS terminal req.
$153.33
Spread vs growth
-130.7%
5Y implied EPS CAGR
46.2%
EPS terminal req.
$185.53
Spread vs growth
-100.2%
10Y implied EPS CAGR
26.8%
EPS terminal req.
$298.80
Spread vs growth
-80.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.9%
Start / end P/E
21.5x → 62.2x
EPS bridge
60.35 → 27.78
Residual
-102.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.